Transcode Therapeutics Inc.
13F holders, Q2 2024 (June 30)15holders +8
10new positions
2sold out
1famous investor
$1.00avg. 13F price*
At the end of Q2 2024, 15 institutions reported holding Transcode Therapeutics Inc. in their 13F filings, up 8 from Q1 2024. 10 opened new positions and 2 sold out. The largest holders were UBS Group AG ($75K), Geode Capital Management, LLC ($39K) and Citadel Advisors ($26K). One famous investor held it Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- Transcode Therapeutics Inc.
- CUSIP
- 89357L303
- Latest filing quarter
- Q3 2024
History
Number of 13F holders
Total Exit/New Position Q1 2024 → Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 10 | $224K |
| Exits | 2 | $229K |
All 13F filers, Q1 2024 → Q2 2024: 225,994 shares bought and 380,920 shares sold, net −154,926 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 15 holders
| UBS Group AG | 0.00% | New | 74,924 | $75K |
| Geode Capital Management, LLC | 0.00% | New | 38,398 | $39K |
| Citadel Advisors | 0.00% | New | 25,512 | $26K |
| Susquehanna International Group, LLP | 0.00% | New | 24,253 | $24K |
| Sheets Smith Wealth Management | 0.00% | New | 20,138 | $20K |
| Virtu Financial LLC | 0.00% | Reduce -66.8% | 18,358 | $18K |
| Private Capital Management LLC | 0.00% | New | 17,518 | $18K |
| Two Sigma Securities, LLC | 0.00% | Reduce -41.5% | 12,854 | $13K |
| Captrust Financial Advisors | 0.00% | New | 11,250 | $11K |
| Morgan Stanley | 0.00% | New | 10,000 | $10K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +59.8% | 7,873 | $8K |
| Financial Network Wealth Advisors LLC | 0.00% | New | 1,000 | $1K |
| Bank of America Corp. | 0.00% | New | 55 | $55 |
| First Personal Financial Services | 0.00% | No change | 1 | $1 |
| Royal Bank of Canada | 0.00% | No change | 1 | $0 |
"% of holder's portfolio" is TRANSCODE THERAPEUTICS INC's weight in each manager's 13F, not the share of Transcode Therapeutics Inc. the manager owns.